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The differential short- and long-
term effects of HIV-1 latency-
reversing agents on T cell function
G. Clutton1, Y. Xu1, P. L. Baldoni2, K. R. Mollan3, J. Kirchherr4, W. Newhard5, Kara Cox5, 
J. D. Kuruc4, A. Kashuba6, R. Barnard5, N. Archin4, C. L. Gay4, M. G. Hudgens2, 
D. M.  Margolis1,4 & N. Goonetilleke1,4
Despite the extraordinary success of HIV-1 antiretroviral therapy in prolonging life, infected individuals 
face lifelong therapy because of a reservoir of latently-infected cells that harbor replication competent 
virus. Recently, compounds have been identified that can reverse HIV-1 latency in vivo. These latency- 
reversing agents (LRAs) could make latently-infected cells vulnerable to clearance by immune cells, 
including cytolytic CD8+ T cells. We investigated the effects of two leading LRA classes on CD8+ T cell 
phenotype and function: the histone deacetylase inhibitors (HDACis) and protein kinase C modulators 
(PKCms). We observed that relative to HDACis, the PKCms induced much stronger T cell activation 
coupled with non-specific cytokine production and T cell proliferation. When examining antigen-
specific CD8+ T cell function, all the LRAs except the HDACi Vorinostat reduced, but did not abolish, 
one or more measurements of CD8+ T cell function. Importantly, the extent and timing of these effects 
differed between LRAs. Panobinostat had detrimental effects within 10 hours of drug treatment, 
whereas the effects of the other LRAs were observed between 48 hours and 5 days. These observations 
suggest that scheduling of LRA and CD8+ T cell immunotherapy regimens may be critical for optimal 
clearance of the HIV-1 reservoir.
A major advance in HIV-1 eradication strategies has been the identification of compounds in different drug 
classes that can reactivate HIV-1 in latently-infected cells. These putative latency-reversing agents (LRAs) include 
histone deacetylase inhibitors (HDACis) that can induce viral transcription from the HIV-1 LTR promoter by 
disrupting the repressive chromatin state induced by histone deacetylases1,2, and protein kinase C modulators 
(PKCms) that can trigger viral RNA expression by activating transcription factors downstream of protein kinase 
C3–5. Promisingly, three HDACis, Vorinostat, Romidepsin, and Panobinostat, have increased plasma viral RNA 
in HIV-1-infected, durably suppressed individuals, suggesting successful HIV-1 reactivation6–9. However, con-
sistent with in vitro studies demonstrating that reactivated cells do not die from viral cytopathic effects10, HDACi 
dosing of participants did not produce decreases in cell-associated viral DNA. These observations suggest that, 
alone, LRAs do not reduce the size of the HIV-1 reservoir and that additional strategies will be needed to purge 
latently-infected cells that have been reactivated.
Recent studies have demonstrated that HIV-1-specific CD8+ T cells can detect and eliminate latently-infected 
cells following in vitro latency reversal10–12. Deng and colleagues reported that despite detectable T cell escape 
mutations in proviral DNA, combination anti-retroviral (cART)-treated chronically HIV-1-infected individuals 
retained CD8+ T cell clones capable of eliminating autologous infected CD4+ T cells12. The authors also showed 
that the clearance of infected CD4+ T cells was further enhanced by prior expansion of CD8+ T cells targeting 
conserved HIV-1 epitopes. These observations provide a clear rationale for using latency-reversing agents in 
combination with immunotherapeutic strategies to boost the endogenous HIV-1-specific CD8+ T cell response 
and/or redirect the response toward conserved epitopes. However, since both HDACis and PKCms have been 
reported to have immunomodulatory effects13–16, it is important to consider whether these agents may impact the 
1Department of Microbiology & Immunology, UNC Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA. 
2Department of Biostatistics, UNC Chapel Hill, Chapel Hill, North Carolina, USA. 3Lineberger Comprehensive Care 
Center, UNC Chapel Hill, Chapel Hill, North Carolina, USA. 4Department of Medicine and UNC HIV Cure Center, 
UNC Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA. 5Merck Research Laboratories, White Horse 
Junction, Pennsylvania, USA. 6Eshelman School of Pharmacy, UNC Chapel Hill, North Carolina, USA. Correspondence 
and requests for materials should be addressed to N.G. (email: nilu_goonetilleke@med.unc.edu)
Received: 11 April 2016
Accepted: 07 July 2016
Published: 02 August 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:30749 | DOI: 10.1038/srep30749
ability of CD8+ T cells to respond to viral antigen. Recently, Jones et al. reported that HDACis impaired HIV-
1-specific CD8+ T cell responses in vitro17, but this was not observed by Sung et al.11, and in clinical studies there 
was no reduction in the frequency of cytokine-producing HIV-1-specific CD8+ T cells following multiple doses 
of Vorinostat or Romidepsin7,8. PKCms have been reported to induce HIV-1 reactivation without proliferation or 
cytokine production in resting CD4+ T cells18,19, but given that PKC activity is central to T cell receptor-mediated 
signaling20, further studies are needed to elucidate their impacts on both antigen presentation and effector func-
tions of T cells.
In this study, we undertook a comprehensive analysis of the effects of clinically relevant doses and exposure 
periods to HDACis and PKCms on T cell activation, cytokine production, production of cytotoxic effectors, and 
proliferation, using PBMC from HIV-1-infected participants durably suppressed on cART. We also measured T 
cell activation and function ex vivo from participants receiving oral Vorinostat. We report that changes in T cell 
phenotype and function were significantly greater and more sustained in PBMC treated with PKCms compared to 
HDACis, but that even within the same class, compounds differed in their effects. Interestingly, some effects were 
only evident 48 hours or more after a short 3 hour exposure to drug. We conclude that the timing of antigen pres-
entation by reactivated cells will be critical in determining whether their clearance by CD8+ T cells is impaired 
following treatment with a LRA.
Results
HDACis minimally activate T cells. The plasma half-lives of Vorinostat, Romidepsin, and Panobinostat in 
vivo are reported as approximately 2 hours, 3.5 hours, and 30 hours, respectively21–23. To mimic in vivo exposure of 
cells to drug we tested the effect of different periods of exposure, 3, 6, 12, or 24 hours, to Vorinostat, Romidepsin, 
and Panobinostat on ex vivo T cell activation. The concentration used for each drug was determined by previously 
reported in vivo plasma Cmax levels that also elicited HIV-1 reactivation in vitro6,9,24,25. PBMC were also exposed to 
PHA/IL-2, which induces generalized T cell activation through cross-linking of T cell receptors and cytokine sig-
naling. After exposure, cells were washed to remove free drug and were maintained in 0.5% DMSO (vehicle) for 
the remaining culture period (Fig. 1a). All measurements were made at 24 hours. LC/MS-MS methods confirmed 
that washing effectively removed drugs from the cell cultures (Table 1).
In the cell cultures exposed to vehicle only, levels of activation markers remained stable between 3 and 24 hours 
(Fig. 1b, Supplementary Fig. S1). The effects on cellular activation following exposure of PBMC to the HDACis 
were modest when compared with PHA/IL-2, which induced significant increases in the frequencies of all activa-
tion markers as well as surface levels of MHC Class I (Supplementary Fig. S2). HDACi exposure had the greatest 
effect on the highly sensitive, early activation marker CD69 (Fig. 1b), with significant increases observed in both 
CD4+ and CD8+ T cells after a 3 hour exposure. Romidepsin had the largest effect (3-fold increase on CD4+ T 
cells and 1.6-fold on CD8+ T cells; p < 0.05 by exact Wilcoxon Signed Rank test), followed by Panobinostat, then 
Vorinostat (1.3-fold mean increase on CD4+ T cells and 1.1-fold on CD8+ T cells; p < 0.05). HDACi exposure 
also induced small but consistent increases in the frequency of CD25 and CD38/HLA-DR-expressing CD8+ T 
cells, the frequency of PD1 positive CD4+ T cells, and a decrease in MHC Class I mean fluorescence intensity 
(MFI). These effects were typically only observed after 6 or more hours of exposure of cells to drug (Fig. 1b).
HDACis did not substantially alter the frequency of memory (CD45RO+ ) CD4+ or CD8+ T cells; similarly 
the activation of memory T cells mirrored those observed for the bulk T cell populations (Supplementary Fig. S3).
The PKC modulator Ingenol 3,20-dibenzoate strongly activates T cells. To investigate whether 
PKCms differed from HDACis in their ability to activate T cells, we repeated the drug washout experiment using 
Ingenol 3,20-dibenzoate (Ingenol-db), which can activate HIV-1 expression in resting primary CD4+ T cells 
from HIV-1-infected individuals on cART26. Measuring PKCm pharmacokinetics is challenging27 and there are 
limited data on the half-life of this drug in vivo. We therefore used the same exposure periods as described above 
to enable a direct comparison with the HDACis, again using PBMC from HIV-1-infected participants durably 
suppressed on cART. A 3 hour exposure to Ingenol-db induced T cell activation to levels comparable to or greater 
than that of PHA/IL-2, with over 90% of CD4+ T cells and 85% of CD8+ T cells expressing CD69 at 24 hours 
(p < 0.05 by exact Wilcoxon Signed Rank test; Supplementary Fig. S2). The frequency of CD25-expressing 
cells and MHC Class I levels were significantly increased on both CD4+ and CD8+ T cell subsets (p < 0.05) 
(Supplementary Fig. S2).
PKCms induce sustained increases in T cell activation. tHaving observed that HDACis and the PKCm 
Ingenol-db induced differing levels of T cell activation at 24 hours, we next assessed the longevity of these effects. 
PBMC from eight HIV-1-seropositive participants durably suppressed on cART were exposed to LRA for 3 or 
6 hours, washed as before, and T cell activation measured at 24, 48, and 72 hours. Due to its modest effects in 
the original experiments, Vorinostat was omitted and two further PKCms, Prostratin and Bryostatin-1, were 
included. Like Ingenol-db, both of these PKCms can reactivate HIV-1 in primary resting CD4+ T cells18,28. 
A 3 hour exposure to the PKCms increased CD69 levels on the majority of CD4+ and CD8+ T cells, which 
was maintained over 72 hours (Fig. 2). Similar effects were observed on CD4+ and CD8+ T cells from HIV-1 
-seronegative participants (Supplementary Fig. S4). The PKCms also induced significant increases in CD25, 
co-expression of CD38 and HLA-DR, PD-1, and MHC Class I that were sustained over 48 to 72 hours. Overall, 
Bryostatin-1 induced the largest and most sustained increases in activation marker expression, followed by 
Ingenol-db and then Prostratin. These effects was comparable to those observed for PHA/IL-2 (Supplementary 
Fig. S5). In contrast, the relatively modest increases in CD69 expression induced by Romidepsin and Panobinostat 
at 24 hours were no longer detected at 72 hours.
Bryostatin-1 reduced the expression of the memory marker CD45RO on CD4+ and CD8+ T cells at 24 hours, 
but these differences were not sustained over 72 hours, and memory (CD45RO+ ) T cells exhibited similar 
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Figure 1. HDACis differentially activate T cells. (a) Experimental design. PBMC from HIV-1-seropositive 
participants durably suppressed on cART (n = 7) were exposed to vehicle (0.5% DMSO) or LRA for 3, 6, 12, 
or 24 hours, washed to remove extracellular drug, and maintained in vehicle for the remaining culture period. 
Activation marker expression was assessed at 24 hours. (b) Expression of activation markers on CD4+ and 
CD8+ T cells at 24 hours. Measurements were compared between vehicle and HDACi treatment using an exact 
Wilcoxon Signed Rank test. * p < 0.05; * * p ≤ 0.016.
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phenotypic changes to bulk T cells (Supplementary Fig. S6). Exposure of PBMC to LRA for 6 hours produced 
broadly similar results to the 3 hour exposure (Supplementary Fig. S7).
In summary, the HDACis Romidepsin and Panobinostat induced minor and short-lived effects on T cell acti-
vation whereas PKCms induced clear and sustained cellular activation.
LRAs have variable toxicity profiles. Within the same experiments, an amine-reactive dye was used to 
assess the viability of PBMC from HIV-1-infected participants on cART. A 3 hour exposure to Romidepsin or 
Panobinostat did not affect viability compared to exposure to vehicle at 24 hours, but viability at 48 and 72 hours 
was significantly reduced (p < 0.05 by exact Wilcoxon Signed Rank test) (Fig. 3). After a longer exposure period 
of 6 hours, Romidepsin and Panobinostat treatment reduced PBMC viability at all time points (p < 0.01). When 
we examined the effects of the PKCms, PBMC exposed to Ingenol-db for 3 but not 6 hours exhibited modestly but 
significantly increased PBMC viability at 24 and 48 hours compared to vehicle-treated PBMC (p < 0.05), suggest-
ing some effects on cell division (see below). In contrast, exposure to Prostratin or Bryostatin-1 (either 3 or 6 hr) 
significantly reduced viability at all subsequent time points (p < 0.01) (Fig. 3). Therefore, the effects of different 
LRAs on viability and activation depended on both the period of exposure to drug and the duration of the culture 
period, with Bryostatin-1 the most toxic, followed by Prostratin, Romidepsin, and Panobinostat.
LRAs have differential effects on pro-inflammatory cytokine release. We next investigated 
whether LRAs promoted pro-inflammatory cytokine release. Three hours exposure to Vorinostat, Panobinostat, 
or Romidepsin did not significantly alter cytokine levels in supernatants collected at 24 hours relative to exposure 
to vehicle (Supplementary Fig. S8). Similarly, no increases in cytokine levels were observed in culture supernatants 
collected 48 and 72 hours after either Romidepsin or Panobinostat exposure (Fig. 4 and Supplementary Fig. S9).
In contrast to the HDACis, Bryostatin-1 significantly increased the concentration of IL-1β , IL-12 (p70), and 
TNFα , but not IL-6, relative to treatment with vehicle. These increases were however modest compared to those 
observed after exposure to PHA/IL-2 (Fig. 4). For example, for IL-1β a mean 5-fold increase relative to vehicle was 
observed in Bryostatin-exposed supernatants compared to a 30-fold increase in PHA/IL-2-exposed supernatants 
at 24 hours (Fig. 4). Bryostatin-1, Ingenol-db, and Prostratin also modestly but significantly increased IFN-γ 
levels in supernatants at 24 hours (Supplementary Fig. S9). Similar results were observed for supernatants from 
cultures exposed to LRA for 6 hours (Supplementary Fig. S9).
PKCms induce significant non-specific cytokine production by CD4+ and CD8+ T cells. We also 
assessed whether LRAs affected the production of cytokines and lytic molecules by T cells in either the presence 
or absence of peptide stimulation. T cell cytolysis is tightly controlled through MHC-TCR signaling29; however, 
agents such as LRAs may have “off-target” effects that dysregulate this process, impacting cellular function. PBMC 
from 10 participants (5 HIV-1-seropositive participants durably suppressed on cART and 5 seronegative partici-
pants) were exposed to Vorinostat, Romidepsin, Panobinostat, Prostratin, Ingenol-db, or Bryostatin-1 for 4 hours, 
washed to remove extracellular drug, and maintained in culture for a further 6 hours. Production of IFN-γ , 
TNFα , and MIP-1β was assessed by intracellular cytokine staining (Supplementary Fig. S10). HDACis did not 
induce non-specific cytokine production by CD4+ or CD8+ T cells (Fig. 5a,b). In contrast, all PKCms induced 
non-specific production of at least one cytokine by CD4+ and CD8+ T cells (Fig. 5a,b). Bryostatin-1 was the most 
potent inducer of TNFα (mean 27-fold increase compared to vehicle for CD4+ T cells and 50-fold for CD8+ T 
cells; p < 0.01 by exact Wilcoxon Signed Rank test stratified by HIV-1 serostatus) and MIP-1β (mean 57-fold for 
CD4+ T cells and 65-fold for CD8+ T cells, p < 0.05). Only Ingenol-db increased non-specific IFN-γ production 
by CD4+ and CD8+ T cells relative to the vehicle control (6-fold for CD4+ T cells and 15-fold for CD8+ T cells, 
p < 0.05). In summary, PKCms, but not HDACis, induced non-specific cytokine production by T cells.
HDACis and PKCms have limited effects on short-term antigen-specific CD8+ T cell cytokine 
and lytic molecule production. In the same set of experiments, we examined whether HDACis and 
PKCms impacted ex vivo antigen-specific CD8+ T cell function. Following stimulation, CD8+ T cells rapidly 
release pre-formed perforin-containing granules, resulting in a reduction in intracellular perforin and the accu-
mulation of CD107a contained in the granule membrane at the cell surface30. To assess cytotoxic T cell function 
and maximize assay stringency, we gated on cells that produced IFN-γ in response to peptide stimulation and 
were CD107a+ and perforinlow 31 (Supplementary Fig. S10). We observed that relative to vehicle, pre-exposure to 
Panobinostat modestly but consistently reduced the frequency of antigen-specific CD8+ T cells exhibiting cyto-
toxic potential in both seropositive and seronegative individuals (mean 1.4-fold (range 1.1–1.7) decrease in sero-
positive; 2.0-fold (range 1.4–2.7) decrease in seronegative; p = 0.002 by exact Wilcoxon Signed Rank test stratified 




Vorinostat Romidepsin Panobinostat Prostratin Ingenol-db Bryostatin-1
Mean CV Mean CV Mean CV Mean CV Mean CV Mean CV
3 < 3.8 N/A < 1.3 N/A < 2.9 N/A < 2.6 N/A 6.25 0.10 5.78 0.07
6 < 3.8 N/A < 1.3 N/A < 2.9 N/A < 2.6 N/A 4.68 0.06 < 5.5 N/A
12 < 3.8 N/A < 1.3 N/A < 2.9 N/A < 2.6 N/A 4.92 0.20 < 5.5 N/A
24 213 0.09 18.7 0.06 7.6 0.07 1099 0.04 97.2 0.04 25.7 0.04
Table 1.  LRAs were removed from cell culture following washing. aMeasured in triplicate by LC-MS/MS. 
N/A: not applicable.
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by HIV-1 serostatus (Fig. 5c)). Ingenol-db, on the other hand, increased the frequency of antigen-specific per-
forinlow CD107a+ IFN-γ + CD8+ T cells (mean 1.6-fold (range 1.2–2.4) increase in seropositive; 1.9-fold (range 
0.8–2.9) in seronegative; p = 0.006). None of the other drugs tested significantly altered the magnitude of this T 
cell response.
Figure 2. PKCms potently activate T cells. Expression of activation markers at 24, 48, and 72 hours on CD4+ 
and CD8+ T cells. PBMC from HIV-1-seropositive participants durably suppressed on cART (n = 8) were 
exposed to vehicle (0.5% DMSO), HDACis or PKCms for 3 hours, washed to remove extracellular drug, and 
maintained in vehicle for the remainder of the 72 hour culture period. Measurements were compared between 
vehicle and LRA treatment using an exact Wilcoxon Signed Rank test. * p < 0.05; * * p ≤ 0.016.
www.nature.com/scientificreports/
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When antigen-specific CD8+ T cell responses involving other combinations of cytokines were assessed, 
Panobinostat exposure consistently decreased antigen-specific CD8+ T cell responses. While Vorinostat had 
no effect on production of lytic markers, exposure modestly reduced the frequency of antigen-specific CD8+ T 
cell responses involving the production of TNFα (p < 0.05; Table 2). Romidepsin did not significantly affect any 
of the functional parameters studied. Among the PKCms, Prostratin did not affect antigen-specific CD8+ T 
cell responses. Ingenol-db and Bryostatin-1, while both strongly inducing non-specific cytokine production 
(Fig. 5a,b), also increased the frequency of CD8+ T cells producing IFN-γ and/or TNFα in response to antigen 
after subtraction of the non-specific response (Table 2). In summary, Panobinostat was the only HDACi, when 
administered at a physiologically-achievable dose that significantly impaired antigen-specific lytic responses in 
primary CD8+ T cells. Among the PKCms, Ingenol-db and Bryostatin-1 enhanced some antigen-specific T cell 
responses.
HDACis and PKCms impair antigen-specific CD8+ T cell proliferation. Another key element of T 
cell function is the capacity to proliferate in response to antigen. PBMC from 10 participants (5 HIV-1-seropositive 
participants receiving cART and 5 seronegative participants) were pulsed with the proliferation-tracking dye 
CFSE, exposed to LRA or vehicle for 4 hours, and washed to remove extracellular drug. Cells were then stimulated 
with either peptide (to assess antigen-specific proliferation) or vehicle (to assess non-specific proliferation) for 5 
days.
We first examined whether LRA exposure impacted PBMC viability over the longer 5 day culture period. 
Vorinostat and Ingenol-db had no impact on viability relative to the vehicle control. Panobinostat and 
Romidepsin reduced viability by a mean of 10 and 14 percentage points respectively (p < 0.01 by exact Wilcoxon 
Signed Rank test stratified by HIV-1 serostatus). The effects of Prostratin and Bryostatin-1 were even greater and 
more variable; mean PBMC viability decreased by 35 percentage points for Prostratin and 32 percentage points 
for Bryostatin-1 (p < 0.01; Fig. 6a).
Vorinostat and Prostratin had no effect on non-specific T cell proliferation as measured by % CFSEdim T 
cells (Fig. 6b,c). This contrasts with Bryostatin-1, which induced significant non-specific CD8+ T cell prolif-
eration compared to the vehicle control, increasing the mean % CSFEdim cells from 0.7% to 31% (p = 0.002); 
Fig. 6b,c). Ingenol-db also increased non-specific CD8+ T cell proliferation to a mean 7% (p = 0.023). A far 
more modest increase in non-specific CD8+ T cell proliferation was also observed following Panobinostat expo-
sure. Interestingly, Romidepsin had no effect CD8+ T cells but reduced non-specific CD4+ T cell proliferation 
(Fig. 6c).
Within the same experiments, we assessed the effects LRA pre-exposure on antigen-specific proliferation, 
measuring the total frequency of CD8+ T cells that had proliferated one or more times in response to antigen (% 
Figure 3. Toxicity of LRAs in vitro. Viability of PBMC from HIV-1-seropositive donors durably suppressed 
on cART (n = 8). PBMC were exposed to vehicle (0.5% DMSO) or LRAs for 3 (left) or 6 (right) hours, washed 
to remove extracellular drug, and maintained in vehicle for the remainder of the culture period. Viability was 
measured at 24, 48, and 72 hours. Measurements were compared between vehicle and HDACi treatment using 
an exact Wilcoxon Signed Rank test. * p < 0.05; * * p ≤ 0.016.
www.nature.com/scientificreports/
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CD8+ T cells CFSEdim), the mean number of divisions undertaken by proliferating (CFSEdim) cells (proliferation 
index), and the mean number of daughter cells generated by each antigen-specific precursor (replication index). Of 
the HDACis, Romidepsin and Panobinostat but not Vorinostat modestly reduced the total frequency of CD8+ T 
cells proliferating in response to antigen (p < 0.01 by exact Wilcoxon Signed Rank test stratified by HIV-
1-serostatus) (Fig. 6d). The PKCms Prostratin and Bryostatin-1, but not Ingenol-db, also reduced the total frequency 
of proliferating antigen-specific CD8+ T cells (p < 0.05) (Fig. 6d). This was not the result of increased death of pro-
liferating cells, as when we repeated the analysis gating first on total (both alive and dead) proliferating CD8+ T 
cells and then assessed their viability, we observed that none of the LRAs reduced proliferating cell viability, 
indeed Ingenol-db and Bryostatin-1-treated cultures harbored fewer dead cells that had proliferated (Fig. 6e). 
Rather, all LRAs except Vorinostat reduced the proliferation index of antigen-stimulated cells (Fig. 6f). Over 5 
days, CD8+ T cells exposed to vehicle followed by antigen proliferated a mean of 4 times. Pre-treatment with 
Romidepsin or Panobinostat reduced the proliferation index to 3.4 and 3.3 respectively (p < 0.01). For PBMC 
pre-exposed to PKCms, Prostratin reduced the proliferation index to 2.8, Ingenol-db to 2.3, and Bryostatin-1 
to 1.4 (p < 0.01). Romidepsin, Panobinostat, Prostratin, Ingenol-db, and Bryostatin-1 also reduced the replica-
tion index of antigen-stimulated CD8+ T cells (STATS; Fig. 6g). These observations suggested that these drugs 
induced cell cycle arrest of antigen-specific CD8+ T cells.
Ex vivo effects of Vorinostat on T cell phenotype and function are minimal. We also examined 
the phenotype and function of T cells from three durably-suppressed HIV-1-seropositive donors who received a 
single 400 mg oral dose of Vorinostat. Plasma Vorinostat levels were monitored for 10 hours post-dose (Fig. 7a). 
PCR analysis using cells obtained by leukapheresis 4 hours after the dose indicated that Vorinostat had induced 
viral reactivation (defined as a significant increase in cell-associated viral RNA from baseline) in participant A 
but not participant B (no data available for participant C) (Fig. 7b). T cell activation was examined on cells freshly 
isolated from peripheral blood obtained immediately prior to the dose (time 0) and at 4, 7, 10, and 24 hours 
post-dose. Most markers were unchanged from baseline (Fig. 7c, Supplementary Fig. S11). However, we observed 
a consistent increase in the frequency of CD25-expressing CD4+ T cells (2.9-fold for participant A, 1.7-fold for B, 
and 6.0-fold for C) and CD8+ T cells (3.2-fold for participant A, 2.7-fold for B and 26.3-fold for C) 24 hours after 
the dose (compared to time 0). No other changes were consistent across the 3 subjects studied, though in 2 of 3 
participants we observed increases in PD-1 frequencies, and in one participant there was a substantial decline in 
the frequency of circulating CD69+ T cells (9.5-fold for CD4+ T cells and 14.8-fold for CD8+ T cells) at 10 hours 
post-dose, maintained at 24 hours post-dose. These changes were not observed when this participant underwent 
leukapheresis without receiving Vorinostat on a previous visit (open circles, Fig. 7c), though on this visit we were 
unable to obtain a blood sample at 24 hours and so cannot exclude a possible effect of the leukapheresis procedure 
on the differences we observed 24 hours after Vorinostat dosing.
Memory (CD45RO+) T cells exhibited similar changes to those seen in the bulk T cell populations 
(Supplementary Fig. S12). We did not observe substantial changes in the frequency of circulating memory 
(CD45RO+ ) T cells (Supplementary Fig. S12), or the relative frequencies of naïve, central memory, effector memory, 
terminally differentiated, or resting CD4+ T cells (Supplementary Fig. S11).
CD8+ T cell function was also assessed, using cryopreserved PBMC, at the same time points. A modest 
(1.4-fold) decrease in the frequency of HIV-1-specific perforinlow CD107a+ IFN-γ + CD8+ T cells was observed 
in participant A. In participants B and C, the T cell response was close to the cutoff for positivity (see Methods) 
at all time points and was of similar magnitude at 0 and 24 hours (Fig. 7d). While our numbers are low, these 
ex vivo data were consistent with our in vitro functional studies in suggesting that Vorinostat does not impact the 
frequency of circulating antigen-specific CD8+ T cells.
Figure 4. Cytokine release following PBMC exposure to LRAs. Cytokine concentrations in culture 
supernatants of PBMC from HIV-1-seropositive participants durably suppressed on cART (n = 5–8). 
PBMC were exposed to vehicle (0.5% DMSO) or LRAs for 3 hours, washed to remove extracellular drug, 
and maintained in vehicle for the remainder of the culture period. Supernatants were collected at 24, 48, and 
72 hours. * p < 0.05; * * p ≤ 0.016.
www.nature.com/scientificreports/
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Discussion
In this study, we assessed the impact of selected HDACis and PKCms on T cell activation, cytokine production, 
lytic function, and proliferation. We observed different effects of these drugs in both short- and longer-term 
assays. Our observations were largely consistent in HIV-1-seropositive and seronegative participants.
Of the drugs tested, a clinically relevant in vitro exposure to Vorinostat had the smallest effect on T cells. 
Relative to mitogenic stimulation with PHA/IL-2, Vorinostat induced very low levels of T cell activation, even 
when PBMC were continuously exposed to the drug for 24 hours. Vorinostat pre-exposure also had no impact 
Figure 5. Effects of LRAs on non-specific and antigen-specific T cell function. PBMC from HIV-1-
seropositive participants durably suppressed on cART (red symbols; n = 5) and HIV-1-seronegative participants 
(black symbols; n = 5) were exposed to vehicle (0.5% DMSO) or a LRA for 4 hours, washed and then cultured 
for a further 6 hours in either vehicle (to assess non-specific responses) or in the presence of peptides (to assess 
antigen-specific responses). (a,b) Non-specific cytokine production by CD4+ and CD8+ T cells. Dashed 
lines indicate mean responses in vehicle-exposed cultures. (c) The effect of 4 hours pre-exposure to LRAs 
on the frequency of memory CD8+ T cells degranulating (perforinlow CD107a+ ) and producing IFN-γ in 
response to peptide stimulation. PBMC from HIV-1-seropositive participants were exposed to HIV-1 CD8+ 
optimal epitopes, and PBMC from HIV-1-seronegative participants were exposed to a pool of ‘Flu, EBV, and 
CMV (FEC) CD8+ T cell epitopes. Due to sample availability, not all LRAs were tested in all participants. 
Measurements were compared between vehicle and LRA treatment using an exact Stratified Wilcoxon Signed 
Rank test. * p < 0.05; * * p ≤ 0.016.
www.nature.com/scientificreports/
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on HIV-specific CD8+ T cell production of lytic molecules, cytokines (with the exception of a modest decrease 
in TNFα production), or proliferation. Our observations are in agreement with studies that reported Vorinostat 
impairment of antigen-specific responses in primary cells only occurred following prolonged exposure of cells to 
Vorinostat or exposure to non-physiological doses11,17.
Oral Vorinostat dosing also had limited effects on peripheral T cell activation, with the exception of a con-
sistent increase in the frequency of circulating CD25+ T cells. Since Vorinostat did not alter CD25 expression 
in vitro, these changes are more likely associated with previously described effects of Vorinostat on cell migra-
tion32–34 though we did not investigate this directly. The increased frequencies of CD25+ T cells observed did 
not impact the circulating frequency of HIV-1-specific CD8+ T cells able to secrete cytokines and degranulate, 
findings consistent with those of Elliot et al.7. Together, these data suggest that physiologically relevant exposures 
to Vorinostat do not alter T cell phenotype or function ex vivo.
A physiologically relevant dose and period of exposure of Panobinostat modestly increased CD4+ and CD8+ T 
cell activation, and induced limited non-specific proliferation in CD8+ T cells, consistent with clinical studies9. 
However, as has previously been reported17, Panobinostat consistently reduced antigen-specific CD8+ T cell lytic 
and proliferative responses.
Like Vorinostat and Panobinostat, Romidepsin induced modest and transient T cell activation. However, while 
the effects of Vorinostat and Panobinostat on T cell function were largely consistent in short- and longer-term 
assays, Romidepsin’s effects appeared to depend on assay duration. A 4 hour pre-exposure to Romidepsin did 
not affect antigen-specific cytokine production by CD8+ T cells measured over the subsequent 6 hours, but sig-
nificantly reduced antigen-specific proliferation measured over 5 days. We also observed reduced viability in 
Romidepsin-exposed cultures at 48 and 72 hours but not 24 hours after exposure, consistent with a previous 
report of ~25% reduction in viability in PBMC that had been exposed to Romidepsin for 48 hours35. Similarly, 
Jones et al.’s observations that Romidepsin essentially abrogated antigen-specific IFN-γ production by both 
primary T cells and clones were made 36 hours after dosing17. Together, these data suggest delayed effects of 
Romidepsin that have implications for T cell function in clinical regimens involving repeated doses of this drug 
(or Panobinostat). While Søgaard and colleagues did not observe impaired antigen-specific cytokine responses 
in ex vivo-stimulated CD8+ T cells from donors who received multiple doses of Romidepsin8, our data suggest 
that measuring T cell proliferation ex vivo will be important to investigate possible longer-term in vivo effects of 
Romidepsin on CD8+ T cell function.
By comparison to the HDACis, the PKCms Prostratin, Ingenol-db and Bryostatin-1 induced significant and 
sustained activation and robust non-specific cytokine production by T cells. Ingenol-db and Bryostatin-1 also 
increased non-specific T cell proliferation, and Prostratin and Bryostatin-1 were toxic to PBMC in vitro. Recently, 
Laird et al. reported that Bryostatin-1 upregulated CD69 but did not induce toxicity or substantial cytokine pro-
duction in resting CD4 T cells from HIV-1-uninfected individuals18. A recent clinical study also reported that 
an intravenous Bryostatin-1 infusion did not increase soluble CD14 or IL-6 levels in plasma of cART-suppressed 
HIV-1-infected participants; however, at the doses used neither PKC activation nor increases in HIV RNA were 















n (HIV+ )c 10 (5) 10 (5) 10 (5) 10 (5) 10 (5) 10 (5)
Fold-change 0.89 0.91 0.68 1.02 2.00 1.51
CV 0.16 0.29 0.24 0.42 0.37 0.53
p-valued 0.107 0.926 0.002 0.647 0.041 0.047
TNFα + 
n (HIV+ ) 6 (2) 6 (2) 6 (2) 6 (2) 6 (2) 6 (2)
Fold-change 0.67 0.76 0.49 1.17 2.77 2.27
CV 0.42 0.55 0.82 0.35 0.59 1.02
p-value 0.031 0.344 0.094 0.344 0.031 0.344
IFN-γ + TNFα + 
n (HIV+ ) 7 (3) 7 (3) 7 (3) 8 (3) 7 (3) 8 (3)
Fold-change 0.65 0.74 0.57 1.35 2.45 1.91
CV 0.34 0.55 0.56 0.71 0.52 0.41
p-value 0.016 0.672 0.016 0.648 0.094 0.023
IFN-γ + TNFα + 
MIP-1β + CD107a+ 
n 7 (3) 7 (3) 7 (3) 6 (3) 7 (3) 7 (3)
Fold-change 0.67 0.80 0.57 1.00 2.22 0.82
CV 0.31 0.55 0.53 0.23 0.52 0.76
p-value 0.016 0.469 0.016 0.844 0.094 1.000
Table 2.  Effects of pre-exposurea to LRAs on antigen-specific CD8+ T cell functionb. aPBMC were 
exposed to LRA for 4 hours, washed and then stimulated with peptides for 6 hours. bGated on non-naïve 
(naïve = CD45RA + CCR7+ ) CD8 + T cells. cTotal n, with number of HIV-1-seropositive participants in 
brackets. For each function, data were included only if the antigen-specific response met the criteria for 
positivity as defined in the Methods. The number of participants who met these criteria differed between 
different functions. dMeasurements were compared between vehicle and LRA treatment using an exact Stratified 
Wilcoxon Signed Rank test.
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by T cells and myeloid cells16,37,38. Overall, these data suggest that Bryostatin-1 can induce non-specific cytokine 
production and that these effects are unsurprisingly greater in activated than resting cells.
Ingenol-db and Bryostatin-1 induced non-specific T cell proliferation but also markedly curbed the number 
of proliferative cycles undergone by antigen-stimulated T cells. In most cell types, PKC activity inhibits prolifera-
tion, though the effect may be dependent on the phase of the cell cycle39. Ingenol-db and Bryostatin-1 have been 
described as PKC agonists and indeed they initially activate PKC isoforms. However, this activation is followed 
by rapid degradation, leading to a reduction in cellular PKC levels for up to 24 hours40. This means that the short- 
versus longer-term effects of PKC modulators may be different, which could explain the inability of Bryostatin-1 
or Ingenol-db-exposed T cells to divide repeatedly in response to antigen. The sustained reduction of PKC levels 
following administration of PKC modulators also raises the possibility that these compounds may be unable to 
Figure 6. Effects of LRAs on T cell proliferation. PBMC from HIV-1-seropositive participants durably 
suppressed on cART (red symbols; n = 5) and HIV-1-seronegative participants (black symbols; n = 5) were 
exposed to vehicle (0.5% DMSO) or a LRA for 4 hours, washed and then cultured for 5 days in either vehicle 
(to assess non-specific proliferation) or in the presence of peptides (to assess antigen-specific proliferation). 
(a) PBMC viability measured at 5 days. (b,c) Representative histograms (b) and combined data (c) showing 
non-specific proliferation by CD4+ and CD8+ T cells exposed to vehicle or LRA for 4 hours. The frequency 
of proliferating (CFSEdim) cells was measured at 5 days. (d) The effect of 4 hours pre-exposure to LRA on (live) 
CD8+ T cell proliferation (% CFSEdim) in response to peptide, measured at 5 days. (e) Viability of all CD8+ T  
cells that had proliferated one or more times in response to peptide after 5 days. (f) The effect of 4 hours pre-
exposure to LRA on the mean number of cycles of proliferation undergone by (live) antigen-stimulated cells 
over 5 days (proliferation index). (g) The effect of 4 hours pre-exposure to LRA on the mean number of (live) 
daughter cells generated by each antigen-specific parent cell over 5 days (replication index). Dashed lines 
indicate mean responses in vehicle-pre-exposed cultures. Measurements were compared between vehicle and 
LRA-treatment using an exact Stratified Wilcoxon Signed Rank test. * p < 0.05; * * p ≤ 0.016.
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Figure 7. Effects of an oral dose of Vorinostat on T cell phenotype and function ex vivo. Participants received 
a single 400 mg oral dose of Vorinostat. (a) Vorinostat plasma pharmacokinetics in three participants 30 minutes 
to 10 hours after dosing. (b) Quantification of HIV-1 RNA in resting CD4+ T cells at baseline and following oral 
dosing with Vorinostat (data not available for participant C). (c) Expression of activation markers on peripheral 
blood CD4+ and CD8+ T cells immediately prior to dosing and 4, 7, 10 and 24 hours post-dose. (d) Frequency 
of memory CD8+ T cells in peripheral blood degranulating (perforinlow CD107a+ ) and producing IFN-γ in 
response to peptide stimulation pre-dose and 4, 7, 10, and 24 hours post-dose. Measurements of HIV-1 RNA in 
resting CD4+ T cells were compared between baseline and post-dose using a Mann-Whitney test.
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induce sustained HIV-1 transcription, as essential host transcription factors such as NFκ B are activated via the 
PKC pathway.
Collectively, our findings raise concerns regarding the safety of incorporating PKC modulators into HIV cure 
strategies. Bryostatin-1 has been administered to patients undergoing treatment for cancers including metastatic 
renal cell carcinoma, advanced pancreatic carcinoma, and lymphoma, with reported toxicities including myalgia 
and lymphopenia41–43. More recently, Bryostatin-1 was well tolerated in cART-suppressed HIV-1-infected clini-
cal trial participants, but at doses that did not induce viral reactivation36. These findings raise the possibility that 
efficacious doses of PKCms may be associated with toxicities that are unacceptable in cART-suppressed HIV-
1-infected individuals, given their relatively good health and life expectancy44. Numerous reports have demon-
strated that compounds that induce robust HIV-1 transcription also promote the largest degree of generalized T 
cell activation, though direct comparisons between viral reactivation and T cell phenotype have not always been 
made18,36. Strategies to uncouple these phenomena, allowing the potent latency-reversing capabilities of PKC 
modulators to be harnessed while minimizing their immunostimulatory properties, should be actively explored. 
Intriguingly, recent studies have demonstrated that Bryostatin-1 and Prostratin synergized with HDACis in vitro 
to increase HIV-1 mRNA expression in latently-infected cells18,45,46, and such combinations were subsequently 
shown to reduce the effective concentration of Bryostatin-147. Another approach is the synthesis of new, more 
potent, PKC modulator derivatives that are less toxic in vivo compared to their parent molecule48–50, a strategy 
that is particularly attractive considering the limited availability of naturally-occurring PKC modulators.
Even within the same drug class, different HDACis and PKCms had different effects on T cell phenotype and 
function. These differences could be due to the different HDAC and PKC isoforms targeted by the compounds, 
for example, Prostratin can reverse latency by targeting PKCα and θ , whereas Bryostatin-1 mediates reactivation 
primarily via PKCα and δ 4,51. Additionally, the stability of drug binding to its target may affect the outcome; for 
example, Vorinostat shows rapid dissociation kinetics, whereas Romidepsin binds its target proteins with much 
higher affinity52. One important difference between compounds that could have implications for the success of 
“kick and kill” strategies is the timing and duration of effects on antigen-specific CD8+ T cells: Panobinostat and 
Ingenol-db had rapid effects on T cell function, whereas those of Romidepsin, Prostratin, and Bryostatin-1 were 
delayed. The variable timing and duration of the effects we observed could explain the inconsistencies between 
different HIV-1 latency models in terms of whether a particular drug effectively reactivates viral gene expres-
sion53. Following latency reversal, elimination of reactivated cells by HIV-1-specific CD8+ T cells will only be 
possible during a “window of opportunity” in which viral antigen is presented on MHC Class I molecules, and 
any detrimental effects of LRAs on CD8+ T cells during this period could compromise their function. The timing 
and duration of antigen presentation is currently unclear; however, since we observed effects on antigen-specific 
CD8+ T cell responses at times ranging from a few hours to five days after dosing, it is likely that the potential 
effects of LRAs on CD8+ T cell function will need to be considered when designing a latency reversal strategy. 
The longer-term effects, as well as the sustained T cell activation induced by PKC modulators, may also have 
implications for repeated dosing. While none of the LRAs tested induced sustained downmodulation of MHC 
Class I on CD4 T cells nor completely abrogated antigen-specific CD8+ T cell responses in our assays, a critical 
question is whether the detrimental effects we observed in vitro would be sufficient to compromise clearance of 
infected cells in vivo. One way to address this question would be to test the ability of CD8+ T cells from clinical 
trial participants to kill HIV-1-infected cells in viral inhibition assays or latency clearance assays ex vivo before 
and after dosing11.
Our study has some limitations. Given the technical challenges associated with measuring PKC modulator 
pharmacokinetics in vivo27, more work is needed to determine in vitro doses of these compounds that reflect 
efficacious clinically-achievable exposures, particularly as phenotypic and functional outcomes may be highly 
dose-dependent36,54,55. The increased expression of CD25 on T cells after an oral dose of Vorinostat but not fol-
lowing exposure to the drug in vitro suggests that LRAs may have effects on T cell tissue distribution that could 
not be measured in a static in vitro system. We did not directly assess the impact of LRAs on immune cells such 
as macrophages that may play a role in the maintenance of the viral reservoir56,57 and modulating other immune 
cells, including T cells. Our observation that Bryostatin-1 induced expression of IL-12 (p70), which is largely 
produced by myeloid cells, suggests possible modulation of these cells by LRAs, though we cannot exclude the 
possibility that this effect may have been mediated indirectly, via IFN-γ produced by T cells. We were unable to 
model the effect of repeated doses in vitro but will seek to address this issue in future studies using ex vivo samples 
collected from a multi-dose Vorinostat trial58.
These data advance on previous work in a number of ways. To our knowledge, we have conducted the first 
comprehensive analysis of the effects of two major classes of latency reversing agents on T cell activation, cytokine 
production and proliferation in PBMC from HIV-1-infected individuals on cART. We have demonstrated 
the importance of timing when considering whether these compounds impact antigen-specific CD8+ T cell 
responses, providing data that help to reconcile divergent in vitro and in vivo reports7,8,17. By focusing on physio-
logically relevant doses and times of exposure to evaluate the effects of HDACis, our data indicate that the detri-
mental effects of these drugs on CD8+ T cells may be more modest than previously suggested. Finally, we report 
robust non-specific effects of PKC modulators on T cells, highlighting the need to tailor regimens involving these 
drugs to minimize the risk of toxicity in vivo.
Methods
Study subjects. HIV-1-infected participants were recruited from the UNC HIV Clinical Trials Unit. 
Participants (all male; age range 25–65) were receiving stable standard-of-care antiretroviral therapy (range 
2–21 years) and had maintained plasma HIV-1 RNA < 50 copies/ml and a CD4 T cell count of > 300/μ l for ≥ 6 
months before enrolment. Participants receiving oral Vorinostat (donated by Merck Research Laboratories, West 
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Point, PA) were administered a 400 mg dose. HIV-1-seronegative participants were recruited by the UNC CFAR 
Immunology Core.
Ethics Statement. All participants provided written informed consent. All experimental protocols were 
approved by the University of North Carolina Institutional Biomedical Review Board (ethics numbers: 14–0741, 
11–0228, and 13–3613) and carried out in accordance with the relevant guidelines.
Peripheral blood mononuclear cell and plasma isolation. Blood was collected by venipuncture. 
Peripheral blood mononuclear cells (PBMC) and plasma were isolated by density gradient centrifugation and 
frozen within 6 hours of sampling. In selected experiments, leukocytes were obtained from HIV-1-seropositive 
donors by continuous-flow leukapheresis. Unless otherwise stated, PBMC were frozen then stored in liquid nitro-
gen prior to use. Plasma was stored at − 80 °C.
Putative latency-reversing agents (LRAs). Vorinostat (Merck), Romidepsin and Panobinostat 
(both Selleckchem), Prostratin (LC Laboratories), Ingenol 3,20-dibenzoate (Santa Cruz Biotechnology), and 
Bryostatin-1 (NCI) were obtained through the Martin Delaney Collaboratory of AIDS Researchers for Eradication 
(CARE) Pharmacology Core. All compounds were solubilized in DMSO, except Bryostatin-1, which was solubi-
lized in 100% Ethanol. The final drug concentration in all ex vivo experiments was 335 nM for Vorinostat, 20 nM 
for Romidepsin, 20 nM for Panobinostat, 1 μ M for Prostratin, 100 nM for Ingenol 3,20-dibenzoate, and 25 nM for 
Brostatin-1.
T cell activation experiments. Cryopreserved PBMC were thawed and rested at 37 °C overnight in R10 
(RPMI 1640 medium supplemented with 10% fetal bovine serum; Penicillin/streptomycin; 2 nM L-glutamine; 
1 nM sodium pyruvate and 10 mM HEPES). PBMC were cultured in the presence of LRAs at 37 °C. Drug was 
removed by washing PBMC twice with R10. R10 + 0.5% DMSO was used as the vehicle control. The positive con-
trol was 3 μ g/mL PHA + 60 units/mL IL-2. Supernatants were harvested for cytokine analysis (see below). PBMC 
were stained with Zombie NIR viability dye, then CD3-PE-Dazzle 594; CD4-Alexa fluor 488; CD8-Brilliant Violet 
510; PerCP-conjugated CD14, 16, 19, and 56 (dump channel); CD25-PE; CD38-PE-Cy7; CD45RO-Brilliant Violet 
650; CD69-APC; HLA-DR-Alexa-fluor 700; MHC Class I-Pacific blue (clone W6/32); and PD-1-Brilliant Violet 
605 (all Biolegend). Cells were acquired on an LSRII flow cytometer (BD Biosciences) and analyzed using FlowJo 
version 10 (Tree Star). Gates for positive events were positioned using fluorescence minus one (FMO) controls 
(Supplementary Fig. S1). Due to the previously reported downmodulation of CD4 by the PKCms Bryostatin-1 
and Prostratin4,59, in assays where these compounds were used CD3+ CD8- lymphocytes were considered CD4+ 
T cells.
Measurement of LRA concentrations. Samples were extracted by protein precipitation with acetonitrile 
containing internal standard compounds and mixed with water prior to LC-MS/MS analysis. A Waters Atlantis 
T3 reverse phase analytical column was used to separate matrix components from method compounds with 
detection on an AB Sciex API-5000 triple quadrupole mass spectrometer. Calibration standards and QC sam-
ples were prepared in RPMI/10% FBS. The analytical range was 1–1000 ng/mL for Vorinostat, Panobinostat, 
Prostratin, and Ingenol 3,20-dibenzoate, 0.71–710 ng/mL for Romidepsin, and 5–10 000 ng/mL for Bryostatin-1. 
Internal standard compounds were Nevirapine-d3 for Vorinostat, Zidovudine-d4 for Panobinostat, Raltegravir-d3 
for Romidepsin and Prostratin, Ritonavir-d6 for Ingenol 3,20-dibenzoate, and Lopinavir-d8 for Bryostatin-1. 
Vorinostat concentrations in human serum were measured as previously6 at 0.5, 1, 3, and 10 hours after dosing.
Luminex assay. Cytokines and chemokines were measured in undiluted cell culture supernatants using the 
Bio-Plex luminex assay (Bio-Rad) and the MSD Multi-spot Assay system (MSD) according to the manufacturers’ 
instructions. Data were acquired using a Bio-Plex® MAGPIXTM Multiplex Reader (Bio-Rad).
Peptides. Peptides were synthesized by Sigma Genosys. HIV-1 CD8+ optimal epitopes (http://www.hiv.lanl.
gov/content/sequence/ELF/epitope_analyzer.html), grouped by protein (either Gag/Nef or non-Gag/NEF HIV-1 
proteins), were used to measure antigen-specific responses in HIV-1-seropositive participants. A pool of ‘Flu, 
EBV, and CMV CD8+ epitopes60 was used to measure antigen-specific responses in both HIV-1-seropositive and 
-seronegative donors.
Intracellular cytokine staining. Cryopreserved PBMC were thawed and rested at 37 °C overnight in 
R10, then exposed to LRAs for 4 hours. Due to sample availability, not all LRAs were tested in all participants. 
R10 + 0.5% DMSO was the vehicle control. Drug was removed by washing twice with R10, and PBMC were incu-
bated with peptides (2 μ g/mL) for 6 hours at 37 °C in the presence of monensin and CD107a-APC (Biolegend). 
PBMC from HIV-1-seropositive participants were exposed to HIV-1 CD8+ optimal epitopes, and PBMC 
from HIV-1-seronegative participants were exposed to a pool of ‘Flu, EBV, and CMV (FEC) CD8+ epitopes. 
R10 + 0.5% DMSO was the no-peptide control. PBMC were then stained with Zombie NIR viability dye, fol-
lowed by CD3-PE-Dazzle 594; CD4-Alexa fluor 488; CD8-Brilliant Violet 510; PerCP-conjugated CD14, 16, 
19, and 56 (dump channel); CD45RA-Brilliant Violet 650; and CCR7-Brilliant Violet 605 (all Biolegend). They 
were fixed, permeabilized and stained intracellularly with IFN-γ -PE; Perforin-Brilliant Violet 421 (clone B-D48); 
TNFα -Alexa fluor 700 (all Biolegend); and MIP-1β -PE-Cy7 (BD Biosciences). Cells were acquired using an LSRII 
flow cytometer as previously. A minimum of 5000 viable CD8+ events were collected. Responses were expressed 
as frequency of non-naïve CD8+ T cells (CD45RA+ CCR7+ cells were considered naïve). Data were included 
in subsequent analyses if the antigen-specific response of cells pre-exposed to vehicle control met the following 
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criteria: above mean background (vehicle control followed by no-peptide control) + 2 standard deviations, and 
above a threshold of 0.1%.
T cell proliferation assay. Cryopreserved PBMC were thawed and rested at 37 °C overnight in R10, then 
pulsed under rotation with 5 μ M carboxyfluorescein succinimidyl ester (CFSE) for 10 minutes. The reaction was 
quenched with ice cold R10 and excess CFSE removed by washing twice with PBS + 5% FBS. PBMC were then 
exposed to LRA or vehicle (R10 + 0.5% DMSO) for 4 hours, washed and incubated with 2 μ g/mL peptide + 20 
units/mL IL-2 at 37 °C for 5 days. R10 + 0.5% DMSO + 20 units/mL was the vehicle control and 3 μ g/ml PHA + 20 
units/mL IL-2 was the positive control. After 5 days, the PBMC were stained with Zombie NIR viability dye, fol-
lowed by CD3-PE-Dazzle 594; CD4-Brilliant Violet 650 and CD8-Brilliant Violet 510, then acquired using an 
LSRII flow cytometer as previously. Data were analyzed using FlowJo version 10 and ModFitLT version 4 (Verity 
Software House).
Measurement of resting CD4+ T cell-associated RNA. Resting CD4+ T cell-associated HIV RNA was 
quantified as previously6. Total RNA was isolated from 36 pools of 106 resting cells at each time point.
Statistical analyses. Outcomes were compared between paired drug and vehicle samples using an exact 
Wilcoxon Signed Rank test (SAS), and analyses including both HIV-1-seropositive and HIV-seronegative partic-
ipants used an exact Wilcoxon Signed Rank test stratified by HIV-1 status (StatXact version 10). Unpaired meas-
urements of resting CD4+ T cell-associated HIV-1 RNA at baseline and after an oral dose of Vorinostat (Fig. 7) 
were compared using a Mann-Whitney test (Graphpad Prism Version 6). All p-values are 2-sided and were not 
adjusted for multiple comparisons; unadjusted p < 0.05 are displayed in the figures. Where a single measure-
ment is discussed in the text, an exact p-value is given. Where multiple measurements are discussed together, an 
approximate p-value (e.g. p < 0.05) is given.
In this study unadjusted p-values 0.016 and below remained significant at the 0.05 level with false discovery 
rate (FDR) adjustment accounting for the 2336 statistical tests conducted. In all figures, p-values < 0.05 are indi-
cated by one asterisk (* ) and p-values ≤ 0.016 are indicated by two asterisks (* * ).
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